Accolade has a proven team with significant experience in the development of Leukotriene Receptor Antagonists (LTRAs) for allergic conditions
Mitchell Glass, MD
Dr. Mitchell Glass is a 24 year veteran of the pharmaceutical industry. His experience is broad, ranging from senior positions in top ten pharmaceutical companies, to investment in and management of start-ups and biotechs. After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995-6, Dr. Glass was VP and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialisation, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics, Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI 1067 and was a member of the IPO team. Dr. Glass joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and a Main Board Director. Since 2008, Dr. Glass has been a Director of OrphageniX Inc. (gene editing) and AVATAR Biotechnologies (biosimilars) and is now the Executive VP of R&D and CMO of Invion LTD. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
G. John Mohr
Mr. Mohr is a multidimensional drug industry consultant and former executive with expertise in managing emerging company issues. His distinguished career includes management of multi-million dollar brands and building products from ‘bench-to-market’. Prior to co-founded BioAsset Advisors, Mr. Mohr led Business and Corporate Development at CV Therapeutics leading to a major licensing deal and subsequent $1.4 billion M&A transaction with Gilead. Mr. Mohr possesses a portfolio of worldwide contacts and provides significant experience in closing successful licensing and M&A transactions. His experience includes President of Fournier Pharma where he was responsible for operations including clinical development, regulatory and business development activities. He built a strategic partnership with Abbott for TriCor®/ Trilipix, a $1.5 billion cardiovascular brand. While at Merck, he lead Financial Services for North America operations followed by six years of responsibility for Marketing and New Product Planning, including worldwide marketing franchise head for the blockbuster brand Pepcid®. Mr. Mohr is a CPA and a graduate of Drexel University with a BS in Finance & Accounting.
CFO and Director of Business Development
Paul Roessel is a senior director with more than 40 years experience in global corporate strategy, portfolio management, and business development. Mr. Roessel also leads strategy consulting activities at Seale & Associates by helping clients align their corporate strategic direction with emerging global business trends. Seale Associates is an international boutique investment bank with focus on the growth of mid-market companies. Mr. Roessel led the sale of Microposite to James Hardie in Australia. Prior to joining Seale & Associates, Mr. Roessel had extensive experience in global corporate strategy, portfolio management and international business development. Mr. Roessel previously held senior management positions at DuPont, Bristol-Myers Squibb and most recently at Johns Manville, a Berkshire Hathaway Company. Mr. Roessel spent more than 15 years living and working in Europe and is fluent in French, German, and English. Mr. Roessel is a member of the advisory council of Microposite, Inc., an innovative building products company that is based on environmentally friendly composite technologies. Mr. Roessel received his B.A. in Economics from Boston University and served as an officer in U.S. military intelligence stationed in Germany.
James Kemp, MD
Chief Medical Officer
Dr. Kemp is clinical professor of pediatrics in the Division of Immunology and Allergy at the University of California School of Medicine, San Diego, and was the past president of the American Academy of Allergy/Asthma and Immunology. Dr. Kemp earned his medical degree from the University of Virginia School of Medicine, Charlottesville, and completed a residency in pediatrics at Emory University School of Medicine, Atlanta. Dr. Kemp completed a fellowship in pediatric allergy and immunology at the University of California, San Francisco, School of Medicine. University of California School of Medicine, San Diego, California.
Vinod Vijayakumar, DPhil, Oxon
Director of Regulatory Affairs
Dr. Vijayakumar has global experience with a variety of medical device and biomedical technologies from operations management, business development, product development, research, and clinical development perspectives. Dr. Vijayakumar is also the Director of Regulatory Affairs for Invion LTD. Previously, Dr. Vijayakumar was the Director of Technology Assessment and Clinical Operations with Aqumen Biopharmaceuticals, a Japanese ophthalmic therapeutics start-up firm, which was developing the first Japanese technology to successfully complete Phase III clinical trials in the US and India. Dr. Vijayakumar was also a Senior Engineer at Exponent, Inc. where he was a consultant in the Injury Biomechanics Practice and prior to that, a Research Engineer with Cambridge Filter Korea in Seoul, Korea. His doctorate research in the biomechanics of bone fracture and repair was conducted at the University of Oxford, UK and the Ospedale Vittorio Emanuale in Italy.